Please login to the form below

Not currently logged in
Email:
Password:

Grifols

This page shows the latest Grifols news and features for those working in and with pharma, biotech and healthcare.

FDA panel rejects Aradigm/Grifols’ inhaled antibiotic

FDA panel rejects Aradigm/Grifols’ inhaled antibiotic

FDA panel rejects Aradigm/Grifols’ inhaled antibiotic. Further evidence is required to warrant approval according to the US regulator. ... The setback is also a blow to Spanish drugmaker Grifols, which bought into the phase III programme for Linhaliq

Latest news

More from news
Approximately 3 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Deal Watch December 2016 Deal Watch December 2016

    2, 180. Hologic (US). Grifols (Spain). Asset acquisition. Nucleic Acid Testing (NAT) technology for R&D and manufacturing of assays and instruments for blood screening. ... The Gold award is won by Grifols, with a 13.6% rise in share price since the

  • Deal Watch table for November 2013 Deal Watch table for November 2013

    1, 800. Novartis / Grifols. Acquisition. Novartis divestment of its blood transfusion testing unit.

  • Pharma deals during November 2013 Pharma deals during November 2013

    In the same vein, Novartis is reviewing its strategy and announced the divestment of its blood transfusion diagnostics unit for $1.7bn to Grifols as part of its ongoing business review.

  • Deal Watch table for May 2013 Deal Watch table for May 2013

    220. Therasphere/ BTG. Asset purchase. Treatment for liver cancer. 200. Aradigm/ Grifols .

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics